Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) PT at $124.15

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) have received an average rating of "Hold" from the twenty-two ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $124.15.

ZBH has been the topic of several analyst reports. Raymond James reduced their price objective on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Stifel Nicolaus increased their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Barclays lowered their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and raised their target price for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Finally, Royal Bank of Canada lowered their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is owned by insiders.

Remove Ads

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently made changes to their positions in ZBH. Empowered Funds LLC grew its stake in shares of Zimmer Biomet by 6.8% in the 3rd quarter. Empowered Funds LLC now owns 4,135 shares of the medical equipment provider's stock valued at $446,000 after purchasing an additional 265 shares during the last quarter. Natixis Advisors LLC grew its position in Zimmer Biomet by 24.7% in the 3rd quarter. Natixis Advisors LLC now owns 63,651 shares of the medical equipment provider's stock valued at $6,871,000 after buying an additional 12,602 shares during the last quarter. Pathstone Holdings LLC increased its stake in Zimmer Biomet by 5.2% in the 3rd quarter. Pathstone Holdings LLC now owns 73,039 shares of the medical equipment provider's stock valued at $7,885,000 after buying an additional 3,612 shares during the period. Prospera Private Wealth LLC purchased a new position in Zimmer Biomet during the 3rd quarter worth $81,000. Finally, Intech Investment Management LLC lifted its stake in shares of Zimmer Biomet by 21.3% in the 3rd quarter. Intech Investment Management LLC now owns 2,379 shares of the medical equipment provider's stock worth $257,000 after acquiring an additional 417 shares during the period. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Down 0.7 %

Zimmer Biomet stock traded down $0.74 during midday trading on Friday, reaching $110.50. 1,296,857 shares of the stock traded hands, compared to its average volume of 1,496,400. The firm has a market cap of $22.00 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a 50-day simple moving average of $106.86 and a two-hundred day simple moving average of $106.86. Zimmer Biomet has a 12-month low of $97.69 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the company earned $2.20 earnings per share. Research analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.